BIO-TECHNE Corp (TECH) : Segall Bryant Hamill reduced its stake in BIO-TECHNE Corp by 14.84% during the most recent quarter end. The investment management company now holds a total of 606,644 shares of BIO-TECHNE Corp which is valued at $67,270,753 after selling 105,714 shares in BIO-TECHNE Corp , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.BIO-TECHNE Corp makes up approximately 1.71% of Segall Bryant Hamill’s portfolio.
Other Hedge Funds, Including , Texas Permanent School Fund reduced its stake in TECH by selling 1,294 shares or 4.35% in the most recent quarter. The Hedge Fund company now holds 28,454 shares of TECH which is valued at $3,155,264. BIO-TECHNE Corp makes up approx 0.04% of Texas Permanent School Fund’s portfolio.Finemark National Bank Trust reduced its stake in TECH by selling 141 shares or 13.08% in the most recent quarter. The Hedge Fund company now holds 937 shares of TECH which is valued at $104,588. BIO-TECHNE Corp makes up approx 0.01% of Finemark National Bank Trust’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in TECH in the latest quarter, The investment management firm added 9,395 additional shares and now holds a total of 57,329 shares of BIO-TECHNE Corp which is valued at $6,456,392. BIO-TECHNE Corp makes up approx 0.02% of State Board Of Administration Of Florida Retirement System’s portfolio.State Treasurer State Of Michigan boosted its stake in TECH in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 14,900 shares of BIO-TECHNE Corp which is valued at $1,678,485. BIO-TECHNE Corp makes up approx 0.01% of State Treasurer State Of Michigan’s portfolio. Lasalle Street Capital Management added TECH to its portfolio by purchasing 2,111 company shares during the most recent quarter which is valued at $235,334. BIO-TECHNE Corp makes up approx 0.22% of Lasalle Street Capital Management’s portfolio.
BIO-TECHNE Corp opened for trading at $106.38 and hit $107.48 on the upside on Friday, eventually ending the session at $107.15, with a gain of 0.53% or 0.56 points. The heightened volatility saw the trading volume jump to 1,59,659 shares. Company has a market cap of $3,987 M.
On the company’s financial health, BIO-TECHNE Corp reported $0.92 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Aug 17, 2016. Analyst had a consensus of $0.93. The company had revenue of $134.80 million for the quarter, compared to analysts expectations of $128.91 million. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.